CytoDyn ROE 2012-2025 | CYDY

Current and historical return on equity (ROE) values for CytoDyn (CYDY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
CytoDyn ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2025-11-30 $-0.04B $-0.12B 38.14%
2025-08-31 $-0.02B $-0.10B 22.22%
2025-05-31 $0.00B $-0.10B -4.41%
2025-02-28 $-0.01B $-0.09B 7.29%
2024-11-30 $-0.01B $-0.09B 13.66%
2024-08-31 $-0.02B $-0.09B 17.47%
2024-05-31 $-0.05B $-0.12B 42.83%
2024-02-29 $-0.05B $-0.12B 46.09%
2023-11-30 $-0.06B $-0.11B 49.11%
2023-08-31 $-0.07B $-0.12B 64.89%
2023-05-31 $-0.09B $-0.11B 81.50%
2023-02-28 $-0.15B $-0.11B 148.91%
2022-11-30 $-0.18B $-0.12B 222.09%
2022-08-31 $-0.19B $-0.09B 346.19%
2022-05-31 $-0.21B $-0.09B 553.25%
2022-02-28 $-0.19B $-0.02B 953.09%
2021-11-30 $-0.20B $-0.01B 1045.33%
2021-08-31 $-0.19B $-0.03B 1107.25%
2021-05-31 $-0.18B $-0.02B 1717.07%
2021-02-28 $-0.18B $-0.02B 3345.45%
2020-11-30 $-0.18B $-0.01B 7000.00%
2020-08-31 $-0.16B $0.00B 3647.06%
2020-05-31 $-0.14B $0.00B 2074.07%
2020-02-29 $-0.08B $0.00B 964.71%
2019-11-30 $-0.06B $-0.01B 655.56%
2019-08-31 $-0.06B $-0.01B 773.33%
2019-05-31 $-0.06B $-0.01B 520.93%
2019-02-28 $-0.05B $-0.01B 434.04%
2018-11-30 $-0.06B $-0.01B 457.14%
2018-08-31 $-0.05B $-0.02B 392.59%
2018-05-31 $-0.05B $-0.01B 485.71%
2018-02-28 $-0.05B $-0.01B 640.00%
2017-11-30 $-0.04B $-0.01B 894.12%
2017-08-31 $-0.03B $-0.01B -12800.00%
2017-05-31 $-0.03B $0.00B -666.67%
2017-02-28 $-0.02B $0.01B -369.23%
2016-11-30 $-0.02B $0.01B -262.50%
2016-08-31 $-0.02B $0.01B -350.00%
2016-05-31 $-0.03B $0.01B -909.09%
2016-02-29 $-0.03B $0.01B 1320.00%
2015-11-30 $-0.03B $0.00B 496.00%
2015-08-31 $-0.03B $-0.01B 516.67%
2015-05-31 $-0.03B $-0.01B 625.00%
2015-02-28 $-0.01B $0.00B 5600.00%
2014-11-30 $-0.01B $0.00B -560.00%
2014-08-31 $-0.01B $0.00B -247.62%
2014-05-31 $-0.01B $0.00B -260.00%
2014-02-28 $-0.01B $0.01B -300.00%
2013-11-30 $-0.01B $0.01B -488.89%
2013-08-31 $-0.01B $0.00B 0.00%
2013-05-31 $-0.01B $0.00B 720.00%
2013-02-28 $-0.01B $0.00B 444.44%
2012-11-30 $-0.01B $0.00B 327.27%
2012-08-31 $-0.01B $-0.01B 188.24%
2012-05-31 $-0.01B $0.00B 133.33%
2012-02-29 $0.00B $0.00B 84.21%
2011-11-30 $0.00B $-0.01B 76.19%
2011-08-31 $0.00B $-0.01B 106.67%
2011-05-31 $0.00B $-0.01B 177.78%
2011-02-28 $-0.01B $0.00B 628.57%
2010-11-30 $-0.01B $0.00B 1466.67%
2010-08-31 $-0.01B $0.00B 1100.00%
2010-05-31 $-0.01B $0.00B 800.00%
2010-02-28 $0.00B $0.00B 266.67%
2009-11-30 $0.00B $0.00B 100.00%
2009-08-31 $0.00B $0.00B 100.00%
2009-05-31 $0.00B $0.00B 200.00%
2009-02-28 $0.00B $0.00B 200.00%
2008-11-30 $0.00B $0.00B 200.00%
2008-08-31 $0.00B $0.00B 100.00%
2008-05-31 $0.00B $0.00B 0.00%
2008-02-29 $0.00B $0.00B 100.00%
2007-11-30 $0.00B $0.00B 200.00%
2007-08-31 $0.00B $0.00B 300.00%
2007-05-31 $0.00B $0.00B 533.33%
2007-02-28 $-0.01B $0.00B 666.67%
2006-11-30 $0.00B $0.00B 800.00%
2006-08-31 $0.00B $0.00B 600.00%
2006-05-31 $0.00B $0.00B 266.67%
2006-02-28 $0.00B $0.00B 0.00%
2005-11-30 $0.00B $0.00B 0.00%
2005-08-31 $0.00B $0.00B 0.00%
2005-05-31 $0.00B $0.00B 0.00%
2005-02-28 $0.00B $0.00B 0.00%
2004-11-30 $0.00B $0.00B 0.00%
2004-08-31 $0.00B $0.00B 0.00%
2004-05-31 $0.00B $0.00B 0.00%
2004-02-29 $0.00B $0.00B 0.00%
2003-11-30 $0.00B $0.00B 0.00%
2003-08-31 $0.00B $0.00B 0.00%
2003-05-31 $0.00B $0.00B 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.329B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $87.081B 33.08
Zoetis (ZTS) United States $54.822B 19.62
Takeda Pharmaceutical (TAK) Japan $50.721B 10.35
Daiichi Sankyo, - (DSNKY) Japan $37.925B 18.89
BeOne Medicines - (ONC) Switzerland $37.155B 196.98
Sandoz Group AG (SDZNY) Switzerland $34.654B 0.00
United Therapeutics (UTHR) United States $20.325B 17.89
Merck (MKKGY) Germany $19.522B 12.04
Shionogi (SGIOY) Japan $16.214B 14.89
Neurocrine Biosciences (NBIX) United States $13.697B 32.86
Summit Therapeutics (SMMT) United States $13.395B 0.00
IPSEN (IPSEY) France $13.337B 0.00
Ionis Pharmaceuticals (IONS) United States $13.248B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.311B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.236B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.967B 21.19
Grifols, S.A (GRFS) Spain $6.264B 0.00
Stevanato Group S.p.A (STVN) Italy $5.802B 32.47
Crinetics Pharmaceuticals (CRNX) United States $5.214B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.547B 0.00
Corcept Therapeutics (CORT) United States $4.344B 46.93
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.269B 20.27
Indivior (INDV) United States $4.193B 17.11
NewAmsterdam Pharma (NAMS) Netherlands $3.947B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.313B 0.00
Hypermarcas (HYPMY) Brazil $3.192B 21.91
Catalyst Pharmaceuticals (CPRX) United States $3.005B 9.59
Dyne Therapeutics (DYN) United States $2.582B 0.00
Ocular Therapeutix (OCUL) United States $2.369B 0.00
Soleno Therapeutics (SLNO) United States $2.350B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.103B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.959B 23.22
Ardelyx (ARDX) United States $1.927B 0.00
Guardian Pharmacy Services (GRDN) United States $1.924B 37.06
Amylyx Pharmaceuticals (AMLX) United States $1.782B 0.00
Oruka Therapeutics (ORKA) United States $1.720B 0.00
Harrow (HROW) United States $1.679B 103.00
Enliven Therapeutics (ELVN) United States $1.604B 0.00
Collegium Pharmaceutical (COLL) United States $1.489B 7.37
BioCryst Pharmaceuticals (BCRX) United States $1.422B 84.38
Relay Therapeutics (RLAY) United States $1.317B 0.00
Savara (SVRA) United States $1.314B 0.00
Evotec AG (EVO) Germany $1.275B 0.00
Xeris Biopharma Holdings (XERS) United States $1.263B 0.00
Aktis Oncology (AKTS) United States $1.135B 0.00
Theravance Biopharma (TBPH) United States $1.051B 44.13
ARS Pharmaceuticals (SPRY) United States $1.045B 0.00
Cronos Group (CRON) Canada $1.023B 0.00
Xencor (XNCR) United States $0.936B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.877B 20.73
KalVista Pharmaceuticals (KALV) United States $0.836B 0.00
Esperion Therapeutics (ESPR) United States $0.758B 0.00
Nektar Therapeutics (NKTR) United States $0.743B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.688B 6.15
Bioventus (BVS) United States $0.675B 13.81
ProKidney (PROK) United States $0.656B 0.00
Altimmune (ALT) United States $0.561B 0.00
Lexeo Therapeutics (LXEO) United States $0.561B 0.00
Lyell Immunopharma (LYEL) United States $0.549B 0.00
Zevra Therapeutics (ZVRA) United States $0.511B 0.00
Organogenesis (ORGO) United States $0.508B 0.00
Elite Pharmaceuticals (ELTP) United States $0.494B 0.00
Aclaris Therapeutics (ACRS) United States $0.491B 0.00
Siga Technologies (SIGA) United States $0.482B 6.60
4D Molecular Therapeutics (FDMT) United States $0.462B 0.00
Nature's Sunshine Products (NATR) United States $0.429B 25.56
USANA Health Sciences (USNA) United States $0.412B 11.48
Aquestive Therapeutics (AQST) United States $0.397B 0.00
Cybin (HELP) Canada $0.385B 0.00
Akebia Therapeutics (AKBA) United States $0.382B 0.00
Aldeyra Therapeutics (ALDX) United States $0.314B 0.00
Protara Therapeutics (TARA) United States $0.305B 0.00
Avalo Therapeutics (AVTX) United States $0.301B 0.00
OmniAb (OABI) United States $0.298B 0.00
Achieve Life Sciences (ACHV) Canada $0.294B 0.00
Relmada Therapeutics (RLMD) United States $0.290B 0.00
Larimar Therapeutics (LRMR) United States $0.286B 0.00
Fractyl Health (GUTS) United States $0.284B 0.00
Profound Medical (PROF) Canada $0.281B 0.00
Silence Therapeutics (SLN) United Kingdom $0.275B 0.00
Heron Therapeutics (HRTX) United States $0.266B 0.00
Journey Medical (DERM) United States $0.251B 0.00
Enlivex Therapeutics (ENLV) Israel $0.249B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.231B 0.00
Galectin Therapeutics (GALT) United States $0.228B 0.00
MediWound (MDWD) Israel $0.225B 0.00
Century Therapeutics (IPSC) United States $0.202B 0.00
AleAnna (ANNA) United States $0.187B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Surrozen (SRZN) United States $0.171B 0.00
Minerva Neurosciences (NERV) United States $0.169B 0.00
Context Therapeutics (CNTX) United States $0.164B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
VAXART, INC (VXRT) United States $0.159B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.156B 0.00
Unicycive Therapeutics (UNCY) United States $0.153B 0.00
Prelude Therapeutics (PRLD) United States $0.139B 0.00
Inhibikase Therapeutics (IKT) United States $0.135B 0.00
Avita Medical (RCEL) United States $0.126B 0.00
Incannex Healthcare (IXHL) Australia $0.124B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.124B 0.00
Karyopharm Therapeutics (KPTI) United States $0.122B 0.00
Cassava Sciences (SAVA) United States $0.112B 0.00
Vivani Medical (VANI) United States $0.107B 0.00
Pyxis Oncology (PYXS) United States $0.106B 0.00
Cardiol Therapeutics (CRDL) Canada $0.104B 0.00
Korro Bio (KRRO) United States $0.099B 0.00
Champions Oncology (CSBR) United States $0.096B 40.76
Gain Therapeutics (GANX) United States $0.080B 0.00
PolyPid (PYPD) Israel $0.076B 0.00
Assertio Holdings (ASRT) United States $0.075B 0.00
NRx Pharmaceuticals (NRXP) United States $0.069B 0.00
Dominari Holdings (DOMH) United States $0.068B 0.00
Metagenomi Therapeutics (MGX) United States $0.066B 0.00
Acrivon Therapeutics (ACRV) United States $0.064B 0.00
Arch Biopartners (ACHFF) Canada $0.062B 0.00
Rafael Holdings (RFL) United States $0.062B 0.00
PMV Pharmaceuticals (PMVP) United States $0.061B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.060B 50.50
Lipocine (LPCN) United States $0.058B 0.00
ElectroCore (ECOR) United States $0.056B 0.00
Nutriband (NTRB) United States $0.055B 0.00
Lite Strategy (LITS) United States $0.049B 0.00
Talphera (TLPH) United States $0.047B 0.00
Telomir Pharmaceuticals (TELO) United States $0.046B 0.00
Plus Therapeutics (PSTV) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.039B 0.00
Wellgistics Health (WGRX) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.034B 0.00
Jupiter Neurosciences (JUNS) United States $0.032B 0.00
SCYNEXIS (SCYX) United States $0.032B 0.00
TherapeuticsMD (TXMD) United States $0.030B 0.00
Natural Alternatives (NAII) United States $0.027B 0.00
Klotho Neurosciences (KLTO) United States $0.025B 0.00
Liminatus Pharma (LIMN) United States $0.021B 0.00
Scienture Holdings (SCNX) United States $0.021B 0.00
Traws Pharma (TRAW) United States $0.020B 0.03
Inotiv (NOTV) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Cosmos Health (COSM) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.019B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
Vyome Holdings (HIND) United States $0.016B 0.00
Tempest Therapeutics (TPST) United States $0.015B 0.00
Mannatech (MTEX) United States $0.014B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
BioVie (BIVI) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00